We are excited to announce the launch of new products from the combined PerkinElmer-Cisbio reagent portfolio.
Using the HTRF® technology:
2 assays to monitor e-NOS which controls blood vessel dilation, blood pressure, and numerous other anti-atherosclerotic and vasoprotective effects
2 assays to detect total and phosphorylated PLCG1, a cytoplasmic tyrosine kinase that plays a crucial role in signal transduction
2 kits to detect the expression of Cereblon, an E3 ubiquitin ligase. Cereblon is a direct target of the immunomodulatory drugs (IMiDs) Thalidomide, Pomalidomide, and Lenalidomide, that are all FDA approved drugs for the treatment of multiple myeloma. IMiDs have recently been derived into PROTAC molecules in order to direct degradation of undesired proteins by the UPS.
Using the AlphaLISA® SureFire® Ultra™ technology
Using the AlphaLISA® SureFire® Ultra™ Multiplex technology:
ERK1/2 p-(Thr202/Tyr204) + ERK Total (New formulation)
For all the Alpha® products, please contact your local representatives or visit www.perkinelmer.com